These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29285961)

  • 1. Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children.
    Angsuwatcharakon P; Khomvilai S; Limsuwun K; Ratananpinit N; Khamchat A; Sanitnai T; Tantawichien T
    Expert Rev Vaccines; 2018 Feb; 17(2):185-188. PubMed ID: 29285961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.
    Tantawichien T; Sibunruang S; Tantawichien T; Angsanakul J; Benjavongkulchai M; Limsuwan K; Udomchaisakul P; Khomvilai S; Sitprija V
    Expert Rev Vaccines; 2014 Dec; 13(12):1593-601. PubMed ID: 25315021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Sudarshan MK; Narayana DH; Giri A; Muhamuda K; Ravi V; Vakil HB; Malerczyk C
    Hum Vaccin; 2006; 2(5):200-4. PubMed ID: 17035734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
    Wongsaroj P; Udomchaisakul P; Tepsumethanon S; Khawplod P; Tantawichien T
    Vaccine; 2013 Mar; 31(13):1748-51. PubMed ID: 23370149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).
    Lang J; Cetre JC; Picot N; Lanta M; Briantais P; Vital S; Le Mener V; Lutsch C; Rotivel Y
    Biologicals; 1998 Dec; 26(4):299-308. PubMed ID: 10403033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Suja MS
    Int J Infect Dis; 2004 May; 8(3):175-9. PubMed ID: 15109593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine.
    Briggs DJ; Banzhoff A; Nicolay U; Sirikwin S; Dumavibhat B; Tongswas S; Wasi C
    Bull World Health Organ; 2000; 78(5):693-8. PubMed ID: 10859864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.
    Quiambao BP; Lang J; Vital S; Montalban CG; Le Mener V; Wood SC; Miranda E
    Acta Trop; 2000 Feb; 75(1):39-52. PubMed ID: 10708006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine.
    Jones RL; Froeschle JE; Atmar RL; Matthews JS; Sanders R; Pardalos J; Moeller L; Chin JE; Famula M; Briggs DJ; Lang J
    Vaccine; 2001 Sep; 19(32):4635-43. PubMed ID: 11535311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection.
    Khawplod P; Wilde H; Sirikwin S; Benjawongkulchai M; Limusanno S; Jaijaroensab W; Chiraguna N; Supich C; Wangroongsarb Y; Sitprija V
    Vaccine; 2006 Apr; 24(16):3084-6. PubMed ID: 16494972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Rasuli A; Houillon G
    Vaccine; 2020 May; 38(21):3740-3746. PubMed ID: 32280042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine.
    Arora A; Moeller L; Froeschle J
    J Travel Med; 2004; 11(4):195-9. PubMed ID: 15541220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized non-inferiority clinical study to assess post-exposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes.
    Bose A; Munshi R; Tripathy RM; Madhusudana SN; Harish BR; Thaker S; Mahendra BJ; Gunale B; Gogtay NJ; Thatte UM; Mani RS; Manjunath K; George K; Yajaman AB; Sahai A; Dhere RM; Alex RG; Adhikari DD; Abhilash ; Raghava V; Kumbhar D; Behera TR; Kulkarni PS
    Vaccine; 2016 Sep; 34(40):4820-6. PubMed ID: 27554534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine.
    Sampath G; Madhusudana SN; Sudarshan MK; Ashwathnarayana DH; Mahendra BJ; Ullas TP; Mohan K; Madhusudhan SK; Ravish HS
    Vaccine; 2010 May; 28(24):4086-90. PubMed ID: 20403351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).
    Ashwathnarayana DH; Madhusudana SN; Sampath G; Sathpathy DM; Mankeshwar R; Ravish HH; Ullas PT; Behra TR; Sudarshan MK; Gangaboraiah ; Shamanna M
    Vaccine; 2009 Dec; 28(1):148-51. PubMed ID: 19818720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postexposure rabies prophylaxis completed in 1 week: preliminary study.
    Shantavasinkul P; Tantawichien T; Wilde H; Sawangvaree A; Kumchat A; Ruksaket N; Lohsoonthorn V; Khawplod P; Tantawichien T
    Clin Infect Dis; 2010 Jan; 50(1):56-60. PubMed ID: 19995217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.